BlackRock, Inc. 13D and 13G filings for Esperion Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2024-11-08 2:17 pm Unchanged |
2024-09-30 | 13G | Esperion Therapeutics, Inc. ESPR |
BlackRock Inc. BLK |
14,265,367 7.300% |
0 (Unchanged) |
Filing |
| 2024-10-22 6:06 pm Purchase |
2024-09-30 | 13G | Esperion Therapeutics, Inc. ESPR |
BlackRock Inc. BLK |
14,265,367 7.300% |
9,620,008 (+207.09%) |
Filing |
| 2023-06-08 1:25 pm Sale |
2023-05-31 | 13G | Esperion Therapeutics, Inc. ESPR |
BlackRock Inc. BLK |
4,645,359 4.900% |
-863,828 (-15.68%) |
Filing |
| 2023-02-07 1:06 pm Purchase |
2022-12-31 | 13G | Esperion Therapeutics, Inc. ESPR |
BlackRock Inc. BLK |
5,509,187 7.500% |
3,267,970 (+145.81%) |
Filing |
| 2022-01-10 12:54 pm Purchase |
2021-12-31 | 13G | Esperion Therapeutics, Inc. ESPR |
BlackRock Inc. BLK |
2,241,217 3.600% |
177,012 (+8.58%) |
Filing |
| 2021-02-05 07:51 am Sale |
2020-12-31 | 13G | Esperion Therapeutics, Inc. ESPR |
BlackRock Inc. BLK |
2,064,205 7.400% |
-4,027 (-0.19%) |
Filing |